Reuters logo
BRIEF-XBiotech announces top-line results for 514G3 antibody therapy in serious staphylococcus aureus infections
April 3, 2017 / 12:14 PM / 6 months ago

BRIEF-XBiotech announces top-line results for 514G3 antibody therapy in serious staphylococcus aureus infections

April 3 (Reuters) - XBiotech Inc

* XBiotech announces top-line results for 514G3 antibody therapy in serious staphylococcus aureus infections

* XBiotech Inc - no drug-related adverse events were observed at any of dose escalation levels for 514G3 antibody therapy

* XBiotech Inc - total of 28 SAES in 15 patients were reported during study period including 4 deaths

* XBiotech Inc - “although deaths observed in treatment arm of study did not appear to be drug-related, this will warrant careful evaluation in larger studies”

* XBiotech Inc - four deaths occurred in treatment arm versus none in placebo group in study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below